TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02061670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed-SPIRE
Description: Intradermal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed-SPIRE
Description: Intradermal injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02230384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active JNJ Drug
Description: 200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active JNJ Drug
Description: 200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
Study: NCT03067571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study: NCT00881127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
Study: NCT03089775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-2000
Description: Experimental

Intervention type: DRUG
Group type: OTHER
Intervention: BBI-2000
Description: Experimental

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: Vehicle Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Comparator

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple treatments
Description: BBI-2000, Vehicle, Clobetasol Propionate, No treatment
Study: NCT00449683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terazosin
Description: off-label use of terazosin to treat antidepressant-induced sweating
Study: NCT02691754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free paracetamol
Description: General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
Study: NCT00593944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1342
Description: MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
Study: NCT01378858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
Study: NCT03146000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine cream
Description: topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam rectal suppository
Description: suppository
Study: NCT03425214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videopolysomnography
Description: Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NC (narcolepsy-cataplexy)
Description: The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
Study: NCT03228355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
Study: NCT01775735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occipital nerve stimulator
Description: Electrical stimulation of the greater occipital nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulator
Description: Electrical stimulation of the greater occipital nerve
Study: NCT02016820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole (suspension)
Description: 1 mg/kg/day

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Modification
Description: Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
Study: NCT00267033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection of orthopaedic cement into vertebral bodies
Description: injection of orthopaedic cement into vertebral bodies
Study: NCT02700997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Clip
Description: Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
Study: NCT03929081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inference Based Approach (IBA)
Description: The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
Study: NCT02371239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Study: NCT00397033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 6mg/day paliperidone er for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 12mg/day paliperidone er for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 weeks
Study: NCT02739620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
Study: NCT03521050

Intervention type: DEVICE
Intervention: defibrillator lead
Description: observation of long-term performance of defibrillator leads
Study: NCT03476941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate Inj 20mg/2ml vial for injection
Description: Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 6 mg/1ml for injection
Description: Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive drain irrigation twice/day
Study: NCT02841098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
Description: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy alone
Description: Optimal medical therapy alone
Study: NCT02923661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM LOC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ball attachment
Study: NCT05772754

Intervention type: GENETIC
Group type: OTHER
Intervention: study of molecular and protein pathways
Description: 42 ml peripheral venous blood sample.

Intervention type: GENETIC
Group type: OTHER
Intervention: study of molecular and protein pathways
Description: 42 ml peripheral venous blood sample.

Intervention type: GENETIC
Group type: OTHER
Intervention: study of molecular and protein pathways
Description: 42 ml peripheral venous blood sample.

Intervention type: GENETIC
Group type: OTHER
Intervention: study of molecular and protein pathways
Description: 42 ml peripheral venous blood sample.

Intervention type: GENETIC
Group type: OTHER
Intervention: study of molecular and protein pathways
Description: 42 ml peripheral venous blood sample.
Study: NCT02660203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced expiration
Description: Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed
Study: NCT02860195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral dose of alcohol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alcotest

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal monitor
Study: NCT02166164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief thermal sensitization
Description: A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long thermal stimulation
Description: A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat-pain-detection threshold
Description: The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
Study: NCT00527436

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: fish oil
Description: Fish oil pills will be taken daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (corn oil) will be taken daily for 12 weeks
Study: NCT04529681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Riskometer Application
Description: Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.

Intervention type: OTHER
Group type: OTHER
Intervention: Informational Leaflets
Description: Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Leaflets
Description: Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
Study: NCT04515225

Intervention type: OTHER
Intervention: Blood Sample
Description: Blood Sample
Study: NCT01788033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: 0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
Study: NCT02575248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2mg
Description: Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 5 mg
Description: Clomiphene citrate 5 mg for induction of ovulation for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate 5 mg
Description: Clomiphene citrate 5 mg for induction of ovulation for three months
Study: NCT01555567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical stimulation will be delivered 2 times per week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical stimulation will be delivered 2 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: Eccentric Exercise will be delivered 2 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: Eccentric Exercise will be delivered 2 times per week
Study: NCT01977820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin
Description: Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
Study: NCT02209298

Intervention type: DEVICE
Intervention: CoreValve Transcatheter Valve
Description: Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
Study: NCT04417764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 knockout engineered T cells
Description: The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10\^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
Study: NCT03087188

Intervention type: OTHER
Intervention: Utilization of inhalator
Description: After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them.
Study: NCT01208584

Intervention type: OTHER
Intervention: fMRI, DTI
Description: functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)

Intervention type: OTHER
Intervention: fMRI, DTI
Description: functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)

Intervention type: OTHER
Intervention: fMRI, DTI
Description: functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)

Intervention type: OTHER
Intervention: fMRI, DTI
Description: functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
Study: NCT04468789

Intervention type: OTHER
Intervention: Six-month ARV dispensing
Description: Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
Study: NCT01854320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral treatment
Study: NCT02306109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard motor rehabilitation treatment
Description: Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive motor rehabilitation treatment
Description: Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
Study: NCT01671540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrapulmonary percussive ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: breathing control exercises
Study: NCT01889082

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Intervention for Young Adults

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Intervention for Young Adults

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Intervention for Young Adults
Study: NCT01892163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: Dexamethasone implant (Ozurdex)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Dexamethasone implant (Ozurdex)
Study: NCT00542295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alverine citrate and simeticone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01924182

Intervention type: DEVICE
Group type: OTHER
Intervention: SynchroMed Infusion System and Intrathecal Morphine Sulfate
Description: Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.

Intervention type: DEVICE
Group type: OTHER
Intervention: SynchroMed Infusion System and Intrathecal Morphine Sulfate
Description: Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Medicine
Description: Subjects will continue to use pain medications as prescribed by their doctor.
Study: NCT01080248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT00147056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate transcranial system
Description: MRI-Guided Focused Ultrasound Feasibility Study for Brain
Study: NCT04993040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: * HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules
Study: NCT03278600

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: tissue-of-origin (ORIGIN-PanCA○R) profiling
Description: 90-gene assay to predict the primary tumor site

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tissue-of-origin (ORIGIN-PanCA○R) profiling
Description: 90-gene assay to predict the primary tumor site
Study: NCT01585272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENA713
Study: NCT03650920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: A HCV negative or previously successfully treated recipient with a HCV positive liver graft